Lu177-DOTATATE: Current Indications and Emerging Approaches

This presentation will discuss the basic compound and evolution of Lu177-DOTATATE. We will review current indications for therapy including the treatment of GEP-NETs and expected outcomes. Finally, we discuss emerging indications for DOTATATE therapy as well as novel radionuclides utilized in current study. 

Target Audience

The activity is designed to meet the interests of radiation oncologists, radiation physicists, radiation biologists, residents and diagnostic radiologists.  

Learning Objectives

Upon completion of this activity, the participants should be able to: 

  • Identify the basics of delivery of Lu177-DOTATATE.
  • Identify the current approved indications and opportunities for further indications for Lu177-DOTATATE.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Course opens: 
03/17/2026
Course expires: 
03/16/2028
Cost:
$0.00
Part of: 
Radiopharmaceutical Therapies Webinar Series
Rating: 
0

Available Credit

  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Price

Cost:
$0.00
Please login or register to take this course.